Candesartan cilexetil(1-(Cyclohexyloxycarbonyloxy)ethyl 1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate) is a typical active pharamaceutical ingredient (API) for the synthesis of antihypertensive drugs. It is the prodrug form of the potent angiotensin II receptor blockers (ARBs, angiotensin II Receptor antagonist). This prodrug is cleaved by esterases within the intestine to liberate the active molecule.
Synthesis and evaluation of novel pyrazolo[1,5-a]pyrimidine derivatives as nonpeptide angiotensin II receptor antagonists.
Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres.
Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension - A population analysis.
Solid-state characterization of candesartan cilexetil (TCV-116): Crystal structure and molecular mobility.
Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans.
Identification, synthesis and structural determination of some impurities of candesartan cilexetil.
A noveland practical synthesis of substituted 2-ethoxy benzimidazole: Candesartan cilexetil.
Development of pulsatile drug delivery for chronotherapeutics of hypertension.